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This editorial refers to ‘HPS2-THRIVE randomized
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Current studies evaluating the efficacy and safety of lipid-targeted
therapies to reduce cardiovascular events are being performed
on the background of statin therapy, given the overwhelming evi-
dence from numerous randomized clinical studies indicating a
reduction of occlusive vascular events by statin therapy.1
Niacin: a lipid-modifying agent
with a long history
Already in 1955 Dr Altschul and colleagues described that high
doses of the vitamin B3 (niacin) reduced serum cholesterol
levels (Figure 1).2 Later, the Coronary Drug Project (CDP) spon-
sored by the National Heart and Lung Institute (published in
1975) tested the efficacy and safety of long-term therapy with a
high dose of niacin (3 g/day) in men after myocardial infarction.3
In the CDP there was no significant effect of niacin therapy on
the primary endpoint, i.e. all-cause mortality, but a significant re-
duction in the rate of recurrent non-fatal myocardial infarction
by 27% was observed.3 The authors concluded that the ‘Coronary
Drug Project data yield no evidence that niacin influences mortality
of survivors of myocardial infarction; this medication may be slight-
ly beneficial in protecting persons to some degree against recur-
rent nonfatal myocardial infarction’, that is to say the authors
were not overly enthusiastic with respect to the efficacy of the
compound to prevent major cardiovascular events. Already in
this early study it became apparent that the adherence to niacin
therapy was significantly reduced as compared with placebo, prob-
ably due to the well-known skin and gastrointestinal side effects of
the compound.3
The niacin receptor GPR109A
and niacin-induced flushing
The mechanisms underlying the effects of niacin on lipids are still
not completely understood, but include a decreased lipolysis due
to inhibition of the hormone-sensitive triglyceride lipase in adipo-
cytes.4 In 2003, the discovery of the niacin receptor, the Gi
protein–coupled receptor GPR109A (HM74A in humans;
PUMA-G in mice) was reported, that later allowed a better under-
standing of the mechanisms underlying the well-known niacin-
associated flush.5 These studies could show that niacin-induced
flushing was mediated by the niacin receptor GPR109A, that was
also thought to mediate the effects of niacin on lipids and on
experimental atherosclerosis.5– 7 Furthermore, it was suggested
that niacin-induced flushing involved the release of prostaglandin
D(2) and prostaglandin E(2), and the respective prostaglandin
D(2) and prostaglandin E(2) receptors,5,6 resulting in the concept
of a blockade of the prostaglandin D(2) receptor-1 to reduce
niacin-induced flushing. Later, a clinical study in 1455 patients
with dyslipidaemia focusing on niacin-induced ‘flushing’ suggested
that the addition of the prostaglandin D(2) receptor-1 antagonist
laropiprant to extended-release (ER) niacin significantly reduced
niacin-associated flushing.8 Moreover, Lukasova et al. suggested in
experimental studies that niacin reduced the progression of ath-
erosclerosis by direct stimulation of GPR109A on immune cells
(e.g. macrophages) leading to reduced inflammatory activation in-
dependent of lipid-modifying effects.7 A subsequent clinical study
by Taylor et al. suggested that addition of ER niacin to long-term
statin therapy resulted in a modest regression of carotid intima-
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media thickness in patients with coronary artery disease or risk
equivalent.9
Clinical outcome trials of niacin in
combination with statin therapy
More recently, two clinical outcome studies (AIM-HIGH and
HPS2-THRIVE) have consequently been evaluating the effects of
ER niacin therapy or the combination of ER niacin with laropiprant
on cardiovascular events in addition to statin therapy.10,11 The
Atherothrombosis Intervention in Metabolic Syndrome with Low
HDL/High Triglycerides: Impact on Global Health Outcomes trial
(AIM-HIGH) was aiming to evaluate the impact of raising
HDL-cholesterol levels with niacin therapy (1.5–2 g/day) on car-
diovascular events in subjects with similar LDL-cholesterol levels
(achieved by higher statin doses and ezetimibe therapy in the com-
parator treatment arm).11 In this study, the primary endpoint, a
composite of the first event of death from coronary heart
disease, non-fatal myocardial infarction, ischaemic stroke, hospital-
ization for an acute coronary syndrome, or symptom-driven cor-
onary or cerebral revascularization, was not reached by niacin
therapy in patients with established cardiovascular disease and an
atherogenic dyslipidaemia.11 In fact, the trial was stopped early
because the boundary for futility had been crossed and a higher
number of ischaemic strokes was observed in patients assigned
to niacin.11 However, the interpretation of the results of the trial
with respect to niacin has been somewhat difficult due to the
design, i.e. the fact that more placebo-treated patients required
increases in the statin dose or addition of ezetimibe, which could
have partly blunted a potential therapeutic benefit of niacin
(Figure 2).
The substantially larger Heart Protection Study 2-Treatment of
HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE)
study has now evaluated the combination of ER-niacin (2 g/day)
with the prostaglandin D(2) receptor-1 antagonist laropiprant
(40 mg) in 25 673 patients with pre-existing occlusive vascular
disease.10 The sponsor of the trial has recently communicated
that the study did not meet its primary endpoint of reduction of
major vascular events, although the detailed data presentation is
still expected. Within this large-scale clinical study, a careful ana-
lysis of the side effects was pre-specified, in particular with
respect to muscle and liver outcomes and reasons for stopping
study treatment that is reported in the European Heart Journal.
The addition of ER niacin/laropiprant to 40 mg simvastatin
therapy (and ezetimibe in some participants) increased the risk
of definite myopathy. The risk of myopathy on the combination
therapy was substantially more pronounced in Chinese patients
as compared with European patients, indicating that the safety of
a drug in one region and in Caucasians cannot necessarily be trans-
lated to other regions, such as Asia.10 Interestingly, although the
name of the trial focuses on the HDL-cholesterol-raising effects
of niacin, there was also a 19.9% reduction of LDL-cholesterol
levels and a 19.5% reduction of triglycerides already in the run-in
phase, and niacin is also known to lower the proatherogenic lipo-
protein(a). The vascular effects of HDL have been observed to be
highly heterogenous, e.g. the endothelial-protective properties of
HDL are impaired in patients with coronary disease or diabetes
as compared with healthy subjects,12–15 which may represent
one mechanisms limiting beneficial effects of HDL-cholesterol-
raising therapies in these patients. The above observations of
Figure 1 Niacin (vitamin B3)—a lipid-modifying agent with a
long history.
Figure 2 Comparison of the AIM-HIGH and the HPS2-THRIVE trial. C, cholesterol; ER, extended release; FU, follow-up.
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substantially lowered LDL-cholesterol levels, however, raise im-
portant questions as to why niacin/laropiprant did not reduce
major cardiovascular events.
Cardiovascular biology of the
prostaglandin D(2) receptor-1?
The question arises of whether the prostaglandin D(2) receptor-1
antagonist laropiprant, that was used to reduce niacin-induced
flushing, is really biologically inert with respect to atherosclerosis
and thrombosis, in particular since little is known about the cardio-
vascular biology of prostaglandin D(2). Interestingly, a recent
experimental study has observed that prostaglandin D(2)
receptor-1 deletion in mice augmented aneurysm formation
and accelerated atherogenesis and thrombogenesis, and these
authors suggested that niacin-induced prostaglandin D(2) release
may function as a constraint on platelets during niacin therapy.16
The effects of inhibition of the prostaglandin D(2) receptor-1 by
laropiprant on thrombosis and atherosclerosis in humans in vivo
are probably difficult to predict and complex, since it has been
observed that on the one hand laropiprant at low concentrations
prevented the inhibitory effects of prostaglandin D(2) on platelet
function, including effects on platelet aggregation and thrombus
formation, but on the other hand laropiprant at higher concentra-
tions attenuated platelet activation induced by thromboxane and
inhibited thrombus formation.17 Similarly, the effects of prostaglan-
din D(2) receptor-1 inhibition on atherosclerotic plaque formation
in mouse models have not been consistent, with accelerated ath-
erosclerosis in some, but not all atherosclerotic mouse models.18
Where do we go from here?
Given the disappointing efficacy results of the two recent clinical
outcome studies of ER niacin in addition to statin therapy and
the increased risk of myopathy observed in the HPS2-THRIVE
study, niacin has failed as a valuable ‘partner’ of statin therapy in
lipid-targeted approaches to reduce major cardiovascular events
further in high-risk patients. There are, however, several large-scale
clinical trials under way that focus either on further LDL-
cholesterol reduction by inhibition of intestinal absorption
(IMPROVE-IT) or PCSK9 antagonism (e.g. ODYSSEY), on com-
bined LDL-cholesterol lowering and HDL-cholesterol raising by
potent cholesteryl ester transfer protein inhibition with anacetra-
pib (HPS3-TIMI55) or evacetrapib (ACCELERATE), or on short-
term HDL raising by infusion (Figure 3).
At present, statin therapy has been clearly shown to reduce vas-
cular events effectively and is reasonably well tolerated in most
patients. We will still have to wait for the results of the above
ongoing studies to see whether another lipid-targeted intervention
can further reduce vascular events in addition to statin therapy. At
the same time, other therapeutic strategies targeting mechanisms
known to be involved in the progression of atherosclerotic vascu-
lar disease, such as anti-inflammatory therapies (low-dose metho-
trexate; interferon-1b antibody),19,20 have been initiated to
determine whether such treatment strategies can further reduce
cardiovascular events in addition to statin therapy with an accept-
able safety profile.
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